STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML

被引：0
|
作者：
Mauro, MJ [1 ]
Druker, BJ [1 ]
机构：
[1] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
LEUKEMIA | 2001年 / 15卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O23
引用
收藏
页码：488 / 488
页数：1
相关论文
共 50 条
  • [41] Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571
    Koyama, N
    Koschmieder, S
    Tyagi, S
    Portero-Robles, I
    Chromic, J
    Myloch, S
    Nurnberger, H
    Rossmanith, T
    Hofmann, WK
    Hoelzer, D
    Ottmann, OG
    CLINICAL CANCER RESEARCH, 2006, 12 (07) : 2025 - 2031
  • [42] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Albitar, M
    Rios, MB
    Shan, J
    Faderl, S
    Garcia-Manero, G
    Issa, JP
    Thomas, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 260B - 260B
  • [43] CML patients with resistance to STI-571 therapy could be monitored by real-time quantification of BCR-ABL transcripts.
    Amabile, M
    Martinelli, G
    Trabacchi, E
    Giannini, B
    Testoni, N
    Terragna, C
    Buonamici, S
    Ottaviani, E
    Soverini, S
    Bassi, S
    De Vivo, A
    Tura, S
    Alberti, D
    Baccarani, M
    BLOOD, 2002, 100 (11) : 320B - 320B
  • [44] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)
    Thiele, J
    Kvasnicka, HM
    Varus, E
    Kriener, S
    Engels, K
    Staib, P
    Ollig, ES
    Griesshammer, M
    Waller, CF
    Pfeifer, H
    Schmitt-Gräff, A
    PATHOLOGE, 2004, 25 (06): : 428 - 435
  • [45] CML patients with complete karyotypic response to STI-571 (Glivec) therapy shows rapid reduction of bcr-abl transcripts.
    Giannini, B
    Martinelli, G
    Rosti, G
    Amabile, M
    Trabacchi, E
    Testoni, N
    Buonamici, S
    Ottaviani, E
    Soverini, S
    Bassi, S
    Pane, F
    Izzo, B
    Saglio, G
    Gottardi, E
    Alberti, D
    Baccarani, M
    BLOOD, 2002, 100 (11) : 785A - 786A
  • [46] Combined treatment of STI571 (Glivec) and curcumin synergistically suppresses the growth of K562 cells via inhibition of Bcr-Abl pathway
    Park, Juwon
    Bae, Eunkyung
    Yoon, Sung-Soo
    Kim, Byoung K.
    BLOOD, 2007, 110 (11) : 206B - 206B
  • [47] Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571
    Barthe, C
    Gharbi, MJ
    Lagarde, V
    Chollet, C
    Cony-Makhoul, P
    Reiffers, J
    Goldman, JM
    Melo, JV
    Mahon, FX
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) : 109 - 111
  • [48] STI571: A tyrosine kinase inhibitor for the treatment of CML - Validating the promise of molecularly targeted therapy
    Druker, BJ
    FASEB JOURNAL, 2002, 16 (04): : A134 - A134
  • [49] Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
    Agarwal, Anupriya
    Fleischman, Angela G.
    Petersen, Curtis L.
    MacKenzie, Ryan
    Luty, Samuel
    Loriaux, Marc
    Druker, Brian J.
    Woltjer, Randall L.
    Deininger, Michael W.
    BLOOD, 2012, 120 (13) : 2658 - 2668
  • [50] Novel tyrosine kinase inhibitors suppress BCR-ABL signaling and induce apoptosis in STI-571 sensitive and resistant CML cells.
    Donato, NJ
    Wu, JY
    Talpaz, M
    Dutia, M
    Fei, Y
    Boschelli, D
    Boschelli, F
    BLOOD, 2002, 100 (11) : 370A - 370A
12345